Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 0.50
Day High 0.52
Open:0.51
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Trailing Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Prometic Life Sciences Inc is a global biopharmaceutical corporation supplying technologies for Bioseparations while also developing its own orphan drugs, plasma-derived therapeutics and small-molecule therapeutic products targeting unmet medical needs.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Prometic announces positive feedback from FDA Type-C meeting on Ryplazim™ (plasminogen) BLA
PR Newswire - Tue Oct 16, 5:30AM CDT
PR Newswire - CMTX
Tue Oct 16, 5:30AM CDT
-- Implementation plan for additional analytical assays and in-process controls confirmed
Prometic to host Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for non alcoholic steatohepatitis (NASH)
- CNW Group - Wed Sep 5, 11:23AM CDT
CNW Group - CMTX
Wed Sep 5, 11:23AM CDT
Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") reported today that it will host a Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome (AS) and a promising therapeutics candidate for the treatment of non-alcoholic steatohepatitis (NASH) on Friday, September 7(th) in New York City.
Prometic Reports Second Quarter 2018 Financial Results and Highlights
PR Newswire - Tue Aug 14, 5:07PM CDT
PR Newswire - CMTX
Tue Aug 14, 5:07PM CDT
-- Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen)
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.43 +18.60% increase
on 10/09/18
Period Open:0.56
Price movement based on the high, low and last over the given period.
0.59 -13.56% decrease
on 10/16/18
-0.05 (-8.93%) decrease
since 09/19/18
3-Month 0.43 +18.60% increase
on 10/09/18
Period Open:0.77
Price movement based on the high, low and last over the given period.
0.80 -36.25% decrease
on 07/23/18
-0.26 (-33.77%) decrease
since 07/19/18
52-Week 0.43 +18.60% increase
on 10/09/18
Period Open:1.63
Price movement based on the high, low and last over the given period.
1.80 -71.67% decrease
on 02/01/18
-1.12 (-68.71%) decrease
since 10/19/17

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement